Opus Genetics secures up to $2M nondilutive funding from Foundation Fighting Blindness for MERTK gene therapy

Opus Genetics, Inc.

Up to $2,000,000 nondilutive funding from Foundation Fighting Blindness Retinal Degeneration Fund for MERTK gene therapy program.
$1,000,000 disbursed upfront; up to $1,000,000 additional upon milestone achievement.
Company must meet development milestones; failure triggers obligation to out-license program.
Regulatory milestone triggers payment equal to total funded amount; tiered royalties until 300% repayment.
On change of control, RDF may require buy-out at 100% of funded amounts.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.